Agios Pharmaceuticals Inc. Product Market Forecast 2015

1
Agios Pharmaceuticals, Inc. - Product Pipeline
Review - 2015
Published on October - 2015
2
.
Report Overview
About Agios Pharmaceuticals, Inc. - Product
Pipeline Review - 2015 Research Beam added report
on Agios Pharmaceuticals, Inc. Product Pipeline
Review - 2015. Summary Global Markets Directs,
Agios Pharmaceuticals, Inc. Product Pipeline
Review - 2015, provides an overview of the Agios
Pharmaceuticals, Inc. s Agios Pharmaceuticals,
Inc. research and development focus. This report
provides comp rehensive information on the
current therapeutic developmental pipeline of
Agios Pharmaceuticals, Inc. s, complete with
comparative analysis at various stages,
therapeutics assessment by drug target, mechanism
of action (MoA), route of administration (RoA)
and molecule type. It also reviews latest
updates, and featured news and press releases,
along with special features on late-stage and
discontinued projects. Get Full Details On
http//www.researchbeam.com/agios-pharmaceuticals-
inc-product-pipeline-review-2015-market
3
.
Report Overview
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes
periodic updation following a stringent set of
processes that ensures that all the profiles are
updated with the latest set of information.
Additionally, processes including live news
deals tracking, browser based alert-box and
clinical trials registries tracking ensure that
the most recent developments are captured on a
real time basis. The report enhances decision
making capabilities and help to create effective
counter strategies to gain competitive advantage.
It strengthens RD pipelines by identifying new
targets and MOAs to produce first-in-class and
best-in-class products. Note Certain sections
in the report may be removed or altered based on
the availability and relevance of data for the
indicated disease.
4
.
Report Overview
Scope The report provides brief overview of Agios
Pharmaceuticals, Inc. including business
description, key information and facts, and its
locations and subsidiaries The report reviews
current pipeline of Agios Pharmaceuticals, Inc.
s human therapeutic division and enlists all
their major and minor projects The report
features product description and descriptive
mechanism of action for key pipeline products
along with the products developmental history and
major milestones Special feature on out-licensed
and partnered product portfolio The report
summarizes all the dormant and discontinued
pipeline projects Latest company statement
Latest news and deals relating to the Agios
Pharmaceuticals, Inc. s pipeline
products  Reasons to buy  Evaluate Agios
Pharmaceuticals, Inc. s strategic position with
total access to detailed information on its
product pipeline
5
Report Overview

• Assess the growth potential of Agios
  Pharmaceuticals, Inc. in its therapy areas of
  focus
• Identify new drug targets and therapeutic classes
  in the Agios Pharmaceuticals, Inc. s RD
  portfolio and develop key strategic initiatives
  to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying
  windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding
  the focus areas of Agios Pharmaceuticals, Inc.
  and exploit collaboration and partnership
  opportunities
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by
  identifying the most promising pipeline of Agios
  Pharmaceuticals, Inc.
• Develop and design in-licensing and out-licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and Scope
• Explore the dormant and discontinued projects of
  Agios Pharmaceuticals, Inc. and identify
  potential opportunities in those areas

6
Table Of Contents
Table of Contents 2List of Tables 4List of
Figures 4Agios Pharmaceuticals Inc. Snapshot
5Agios Pharmaceuticals Inc. Overview 5Key
Information 5Key Facts 5Agios Pharmaceuticals
Inc. - Research and Development Overview 6Key
Therapeutic Areas 6Agios Pharmaceuticals Inc. -
Pipeline Review 8Pipeline Products by Stage of
Development 8Pipeline Products - Monotherapy
9Pipeline Products - Partnered Products
10Partnered Products/Combination Treatment
Modalities 11
7
Table Of Contents
Pipeline Products - Out-Licensed Products
12Out-Licensed Products/Combination Treatment
Modalities 13 Agios Pharmaceuticals Inc. -
Pipeline Products Glance 14Agios Pharmaceuticals
Inc. - Clinical Stage Pipeline Products 14Phase
II Products/Combination Treatment Modalities
14Agios Pharmaceuticals Inc. - Early Stage
Pipeline Products 15Preclinical
Products/Combination Treatment Modalities
15Discovery Products/Combination Treatment
Modalities 16Agios Pharmaceuticals Inc. - Drug
Profiles 17VLA-43 17Product Description
17Mechanism of Action 17RD Progress 17Vaccine
for Undisclosed Indication 19
8
Table Of Contents
Product Description 19Mechanism of Action 19 RD
Progress 19VLA-84 20Product Description
20Mechanism of Action 20RD Progress 20VLA-15
21Product Description 21Mechanism of Action
21Enquiry about this report _at_
http//www.researchbeam.com/agios-pharmaceuticals-
inc-product-pipeline-review-2015-market/enquire-ab
out-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/agios-pharmaceuticals-
inc-product-pipeline-review-2015-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com